natgillin/translations-raw huggingface dataset:
The base station apparatus according to claim 1 wherein DVRBs with non-consecutive DVRB numbers are mapped to two of the PRBs, which are adjacent to each other in the frequency domain. 
Integrirani krug sukladno jednom od zahtjeva 1 do 13, naznačen time da su DVRB-i s ne-uzastopnim DVRB brojevima mapirani na dva od PRB-a koji su susjedni u frekvencijskoj domeni.
The compound of claim 2, wherein both Ra and Ra' together are an oxo (=O) group. 
Spoj u skladu s patentnim zahtjevom 1, naznačen time što su i Ra i Ra′ zajedno skupina okso (=O).
Cell culture is widely used today for the production of various biologically active products, such as viral vaccines, monoclonal antibodies, non-antibody immuno-regulators, polypeptide growth factors, hormones, enzymes, tumor specific antigens, etc. 
Kultura stanica danas se široko koristi za dobivanje različitih biološki aktivnih proizvoda, poput virusnih cjepiva, monoklonskih antitijela, imunoregulatora, polipeptidnih faktora rasta, hormona, enzima, tumor - specifičnih antigena itd.
The solid was added to a biphasic mixture of EtOAc (500 mL) and HCl (5N aq., 300 mL) and stirred for 0.5 h. 
Krutina je dodana bifaznoj smjesi EtOAc (500 mL) i HCI (5N aq., 300 mL) te je miješanje nastavljeno tijekom 0.5 sati.
wherein the self-tailing arrangement comprises: a rope guide channel extending circumferentially around the self-tailing assembly, the rope guide channel being defined by upper and lower rope guide rings, the upper and lower rope guide rings being rotatable with the drum and adapted to grip rope in the rope guide channel; 
žlijeb za vođenje užeta (248) koji se proteže obodno oko uređaja za samopovlačenje, gdje je žlijeb za vođenje užeta definiran s gornjim (244) i donjim (246) prstenovima za vođenje užeta, dok su navedeni gornji i donji prstenovi za vođenje užeta okretni zajedno s bubnjem i namješteni za zahvaćanje užeta u žlijeb za vođenje užeta;
The isolated polynucleotide according to claim 1, wherein the monoclonal antibody or an antigen-binding fragment thereof is capable of specifically binding SEQ ID NO: 37 (Type II 1.0 PGLYRP1) and/or SEQ ID NO: 38 (Type II 2.0 PGLYRP1). 
Monoklonsko antitijelo ili njegov antigen-vezujući fragment u skladu sa patentnim zahtjevom 1, koje je sposobno za specifično vezivanje SEK ID BR: 37 (PGLYRPI 1.0 Tipa II) i/ili SEK ID BR: 38 (PGLYRPI1 2.0 Tipa II).
Preferably, the active ingredients are administered once or twice a day. 
Poželjno se djelatni sastojci daju jedanput ili dvaput na dan.
extracting said gas mixture from said pyrolysis chamber; 
ekstrahiranje (150) navedene smjese plinova (30) iz navedene komore za pirolizu (52);
The crystalline dihydrogenphosphate salt of the present invention exhibits pharmaceutic advantages over the free base and the previously disclosed hydrochloride salt (WO 03/004498) in the preparation of a pharmaceutical drug product containing the pharmacologically active ingredient. 
Kristalna dihidrogenfosfatna sol predmetnog izuma pokazuje farmaceutske prednosti nad slobodnom bazom i prethodno opisanom hidrokloridnom soli (WO 03/004498) u pripravi farmaceutskog produkta - lijeka, koji sadržava farmakološki aktivan sastojak.
As described above the compounds of the invention, 2-(1H-indolylsulfanyl)-benzyl amine derivatives, are serotonin reuptake inhibitors. 
Kako je to gore opisano, spojevi izuma, 2-(1H-indolsulfanil)-benzin amina derivati predstavljaju inhibitore re-apsorpcije serotonina.
In an embodiment of the method according to the invention, wood is impregnated with crude tall oil, resin and/or fatty acids separated from it or a mixture of these. 
Postupak sukladno Zahtjevu 1, naznačen time što je drvo impregnirano sirovom tekućom smolom, smolom i/ili masnim kiselinama odvojenim od nje ili mješavine istih.
A method for preparing a liposome comprising a conjugate according to claim 1 or 2, the method comprising the step of coupling a conjugate according to claim 1 or 2 to a liposome 
Metoda za pripremu liposoma obuhvaća konjugat u skladu s patentnim zahtjevom 1 ili 2, metoda obuhvaća korak spajanja konjugata u skladu s patentnim zahtjevom 1 ili 2 u liposom.
1, characterized in that interleukins are used as proteins, and chain-terminal amino acids are Phe, Ala, Val, Ala, Leu, Ile, etc. Antibacterial agent under p. 
Antibakterijsko sredstvo prema zahtjevu 1, naznačeno time, da proteini sadrže interleukine, a završetak aminokiselinskog lanca obuhvaća strukture Phe, Ala, Val, Leu i Ile.
• one of the movable side guides (14,114) is hinged to its side of the pedestrian way and the other movable side guide (15,115) is able move away from its side throughout its height; or 
* jedna od pomičnih bočnih vodilica (14, 114) zakvačena je na svojoj strani prolaza za osobe, a druga pokretna bočna vodilica (15,115) može se odmaknuti od svoje strane svojom cijelom visinom ili
A counter as claimed in any one of the preceding claims attached to a dispenser having a body for receiving a medicament container and a dispensing mechanism for dispensing a dose of medicament from said container. 
Brojač kao što je zahtijevano u bilo kojem od prethodnih patentnih zahtjeva je vezan za dispenzer (200) koji ima tijelo za prijem kontejnera za medikament i mehanizam za dispenziranje za dispenziranje doze medikamenta iz navedenog kontejnera.
The process of clause 84, characterized by at least one of the following features (1)-(3): 
Postupak prema patentnom zahtjevu 52, naznačen najmanje jednom od slijedećih karakteristika (1)-(3):
The formulation of claim 18, wherein at least 10% of the carboxylic acid groups of said polycarboxylic acid polymer are in the form carboxylate anions. 
Polimer polikarboksilne kiseline koji je bar djelomično neutraliziran, pri čemu bar 90 % skupina karboksilne kiseline polimera polikarboksilne kiseline su u obliku anjona karboksilata.
The aqueous formulation of any of the foregoing claims comprising one or more excipients selected from a group consisting of zinc, m-cresol, glycerol, polysorbate 20 and sodium, preferably comprising 90 µg/mL zinc, 2.7 mg/mL m-cresol and 20 mg/mL glycerol 85% or comprising 90 µg/mL zinc, 2.7 mg/mL m-cresol, 20 µg/mL polysorbate 20 and 20 mg/mL glycerol 85%. 
Vodena formulacija prema bilo kojem od prethodnih patentnih zahtjeva naznačena time da sadrži jedan ili više ekscipijenata odabranih iz skupine koja sadrži cink, m-krezol, glicerol, polisorbat 20 i natrij. Vodena formulacija prema zahtjevu 8 naznačena time da sadrži 90 µg/mL cinka, 2.7 mg/mL m-krezola i 20 mg/mL glicerola 85%. Vodena formulacija prema zahtjevu 8 naznačena time da sadrži 90 µg/mL cinka, 2.7 mg/mL m-krezola, 20 µg/mL polisorbata 20 i 20 mg/mL glicerola 85%.
preparation of the scopine ester of formula I by transesterification of methyl di(2thienyl)glycolate of formula IV with scopine of formula III in the presence of a substoichiometric amount of a sterically hindered base selected from the group of alkali salts of branched C3 to C5 alkoxides in an inert solvent, 
priprave skopin estera formule I [image] putem trans-esterifikacije metil di(2-tienil)glikolata formule IV sa skupinom formule III [image] u nazočnosti substehiometrijske količine odabrane iz skupine alkalijskih soli razgrananog C3 do C5 alkoksida u inertnom otapalu,
constructing an upper shoe assembly, which is composed of at least one vapor-permeable lining (12), a vapor-permeable upper (13), and a waterproof and vapor-permeable upper membrane (14) that is between them, 
- < izradu gornjišta cipele, koje se sastoji najmanje od jedne paropropusne postave (12), paropropusnog gornjišta (13) 1 vodonepropusne i paropropusne membrane gornjišta (14) koja se nalazi između njih
A method of treatment of inflammatory diseases, disorders and conditions characterized by or associated with an undesirable inflammatory immune response, and all diseases and conditions induced by or associated with an excessive secretion of TNF-a and IL-1 which comprises administering to a subject a therapeutically effective amount of a compound according to claim 1 or 2 or 20. 
Upotreba spoja u skladu s bilo kojim od patentnih zahtjeva 1 do 32, ili njegove farmaceutski prihvatljive soli ili solvata, u proizvodnji medikamenta za liječenje upalnih bolesti, poremećaja i stanja, naznačena time, ili povezana s neželjenim upalnim imunosnim odgovorom i svim bolestima i stanjima induciran ili povezanim s prekomjernim lučenjem TNF-q i IL-1.
The method according to claim 1, wherein said mature megakaryocytes are exposed to a shear rate of at least 1000 s−1. 
Metoda u skladu s patentnim zahtjevom 1 ili 2, pri čemu su navedeni zreli megakariociti izloženi naprezanju veličine od barem 1000 s".
The antibody or a functional fragment of the antibody may inhibit the process of cell fusion of osteoclasts. 
Monoklonsko antitijelo ili njegov funkcionalni fragment, sukladno sa zahtjevom 1 ili 2, koji inhibiraju proces fuzije stanica osteoklasta.
a solid-state 13C NMR spectrum with signals at 112.3, 163.9, 168.8 ± 0.2 ppm; 
13C-NMR spektra čvrstog stanja, sa signalima na 112,3, 163,9, 168,8 ± 0,2 ppm;
The process of claim 1, wherein the non-reactive stripping medium is hydrogen, nitrogen, fuel gas or steam. 
Postupak u skladu s patentnim zahtjevom 1, naznačen time, da je nereaktivni medij za stripiranje vodik, dušik, gorivi plin ili para.
The compound of claim 1, selected from the group consisting of 
N I PG za spoj sljedeće formule:
Transformed microalgae according to claim 1 to 7, wherein said glycosylated polypeptide expressed in the transformed microalgae is erythropoietin, a cytokine such as interferons, an antibody, a coagulation factor, an hormone, beta-glucocerebrosidase, pentraxin-3, or an anti-TNF. 
Metoda u skladu sa patentnim zahtjevom 2, gdje navedeni glikozilirani polipeptid eksprimiran u transformiranoj mikroalgi je eritropoetin, citokin, antitijelo, faktor koagulacije, hormon, beta-glukocerebrozidaza, pentraksin-3, ili anti-TNF.
A process for preparing a compound of formula (I): and/or geometric isomers and/or stereoisomers and/or diastereomers and/or salts and/or hydrates and/or solvates thereof, wherein Q represents NR3R4, R1 represents hydrogen or C1-4 alkyl group, R2 represents hydrogen or C1-4 alkyl group, R3 represents hydrogen, C1-4 alkyl group, phenyl or optionally substituted phenyl, R4 represents hydrogen, C1-4 alkyl group, phenyl or optionally substituted phenyl, wherein the term "optionally substituted phenyl" means a phenyl group which can be substituted in any position by one or more halogen, C1-4 alkyl, C1-4 alkoxy, trifluoromethyl and/or cyano group, or combinations thereof comprising reacting an isocyanate of formula (IV): 
predstavlja vodik ili C1-4 alkil skupinu, predstavlja vodik, C1-4 alkil skupinu, fenil ili opcijski supstituirani fenil, predstavlja vodik, C1-4 alkil skupinu, fenil ili opcijski supstituirani fenil, gdje izraz “opcijski supstituirani fenil” znači fenilna skupina koja može biti supstituirana na bilo kojoj poziciji s jednom ili više halogen, C1-4 alkil, C1-4 alkoksi, trifluorometil i/ili cijano skupinom, ili njihovim kombinacijama, pri čemu postupak obuhvaća reakciju izocijanata formule (IV):
This, in turn, causes the phosphorylation of phosphorylase b; thereby converting glycogen phosphorylase to its active a form. 
To pak uzrokuje fosforilaciju fosforilaze b; pri čemu dolazi do konverziju glikogen fosforilaze u svoj aktivni oblik.
combining Candesartan cilexetil or its solvates or hydrates with a solution containing at least one surfactant from the group of anionic surfactants, preferably sodium docusate, and optionally with a second surfactant, preferably a sodium lauryl sulfate, so that Candesartan cilexetil is homogeneously dispersed in the solution; 
kombiniranju kandesartan-cileksetila ili njegovih solvata ili hidrata s vodenom otopinom koja sadrži natrijev dokusat kao prvi surfaktant, te s natrijevim lauril-sulfatom kao drugim surfaktantom, tako da se kandesartan-cileksetil homogeno dispergira u otopini;
from 1400 to 2000 mg of alkaline substances, wherein the aspirin and alkaline substances are contained in a single layer. 
od 1400 do 2000 mg alkalnih tvari, naznačena time da su aspirin i alkalne tvari sadržane u jednom sloju.
A fan assembly as claimed in claim 7, wherein the means for creating an air flow comprises an impeller (64), motor (68) for rotating the impeller, and a diffuser (74) located downstream from the impeller (64). 
Ventilatorski sustav prema zahtjevu 7, gdje sredstva za stvaranje struje zraka obuhvaćaju propeler (64), motor (68) za okretanje propelera, 1 difuzor (74) koji se nalazi nakon propelera (64).
reacting the above compound of formula IIb with 2-bromo-4-fluorophenol to give a compound of formula Mb in the form of diastereoisomeric mixture (R,S+S,S) 
To m) reakciju gore navedenog spoja formule IIb sa 2-bromo-4-fluorofenolom, da bi dobio spoj formule IIIb u obliku dijasteroizomerne smjese (R, S+8, S)
Procedure for the manufacture g Gelatin and 1500 g mannitol were dispersed in 45.01 kg of purified water, while stirring and heating in a vacuum mixer. 
Postupak za proizvodnju 2000 g Želatine i 1500 g manitola raspršeno je u 45,01 kg pročišćene vode, uz miješanje i zagrijavanje u vakuum miješalici.
Conditions that cause changes in microaggregation should be avoided e.g. 
Stanja koja uzrokuju promjene u mikroagregaciji bi trebalo izbjegavati, na pr.
Bound radioactivity is measured using 96-well scintillation counting (Packard Topcount) or by removing the filters from the plate and direct gamma counting. 
Vezana radioaktivnost izmjerena je scintilacijskim mjerenjem u 96 jažica (Packard Topcount), ili skidanjem filtara s ploče, te izravnim mjerenjem y-
Formula 39 was then oxidized to form Formula 40 according to the following reaction: Here, solid Na2SO4 was added to a solution of Formula 39 (24.45g, 24.0 mmol) and 4-methyl morpholine N-oxide (10.1g, 84 mmol) in DCM (340mL) to assure that the reaction was dry. 
Formula 39 Formula 40 Ovdje je krutina Na»SO, bila dodana u otopinu formule 39 (24.4 g, 24.0 mmol) 1 4-tnetil morfolin N-oksida (10.1 g, 84 mmol) u DCM (340 mL) da bi se osiguralo da reakcija bude suha.
The topical gel composition of claim 1, wherein the total polyol comprises about 4.5% to 6.5% (w/w) a first polyol, and one or more additional polyols. 
Kompozicija topičkog gela prema zahtjevu 1, pri čemu ukupni poliol sadrži oko 4,5% do 6,5% (w/w) prvog poliola.
two cat-ion exchange membranes defining a chamber for the starting liquid or the partly AX-REED treated liquid; and 
dvije membrane za izmjenu kationa koje definiraju komoru za početnu tekućinu ili djelomično obrađenu tekućinu s AX-REED; i b.
In a first embodiment, a compound is disclosed for use as a polymerisation agent in coatings, characterized in that it comprises a cobalt-bearing alkyd polymer, said polymer having a cobalt content of 0.5 to 6% by weight, a mean molecular weight of more than 3000, and comprising cobalt carboxylate sequences. 
Spoj za upotrebu kao sredstvo za polimerizaciju u premazima, koji sadrži alkidni polimer s kobaltom sa sadržajem kobalta od 0,5 do 6 % po masi, s prosječnom molekulskom masom većom od 3000 1 s karboksilatnim sekvencama kobalta, čija je značajka to što navedeni polimer ima kiselost manju od 40 mg KOH/g, a poželjno manju od 20 mg KOH/g.
heating the solution resulting from step (i) to a temperature of 80°C for 15 minutes; 
(1i) zagrijavanje otopine dobivene u koraku (1) do temperature od 80%C kroz 15 minuta;
r-hIL-18BP started to elute as a main peak after about 0.5-0.8 BV from the start. 
r-hIL-18BP se počeo eluirati kao glavni pik nakon otprilike 0.5-0.8 BV od početka.
coating a substrate (2) with a liquid reactive composition which can be digitally printed on after drying; 
(a) -premazivanja podloge (2) tekućim reaktivnim pripravkom na koji se nakon sušenja može nanositi digitalni tisak;
Example 1: Production of Form-I Crystal of the Invention 
Datum objave europske prijave patenta:
An “amine-protecting group” is a group capable of protecting the glutamyl a-amine group of a compound of the first aspect of this invention or an intermediate thereto during the synthesis of that compound, and subsequently removable without affecting the remainder of the compound of the first aspect of this invention. 
Â« Amino zaštitna skupina Â« je skupina koja je u mogućnosti zaštititi glutamil a-amin skupinu spoja prvog aspekta izuma ili još k tome intermedijer za vrijeme sinteze tog spoja, a istodobno mogućnost odstranjivanja bez utjecaja na ostatak spoja iz prvog aspekta ovog izuma.
An area bonded spunbond nonwoven fabric comprising continuous bicomponent filaments of polyethylene terephthalate homopolymer including a matrix component melt extruded from a relatively higher intrinsic viscosity polyethylene terephthalate homopolymer and a binder component melt extruded from a relatively lower intrinsic viscosity polyethylene terephthalate homopolymer, and a multiplicity of thermal fusion bonds located throughout the fabric, the fusion bonds consisting of areas in which the binder component has softened and thermally fused to adjacent filaments at points of contact, and wherein both the matrix and binder components are in a semi-crystalline state and exhibit a single melting peak as evidenced by a DSC trace. 
Plošno spojeno vretenom upredeno netkano predivo, naznačeno time, da obuhvaća neprekidne dvokomponentne niti neograničene duljine od polietilen-tereftalat-homopolimera uključujući matrični sastojak ekstrudiran taljenjem od polietilen-tereftalat-homopolimera relativno većeg unutarnjeg viskoziteta te vezni sastojak ekstrudiran taljenjem od polietilen-tereftalat-homopolimera relativno manjeg unutarnjeg viskoziteta, kao 1 mnoštvo termički staljenih spojeva koji se nalaze posvuda u predivu, gdje se staljeni spojevi sastoje od područja u kojima se je vezni sastojak omekšao 1 termički stalio sa susjednim nitima na kontaktnim točkama, te time, da se oba sastojka, i vezni i matrični, nalaze u stanju polukristala, te oni izražavaju jedinstvenu vršnu vrijednost taljenja, kako se prikazuje pomoću DSC-traga.
Briefly, Sprague Dawley rats were orally dosed with rapamycin and derivatives at 2.5 or 10 mg/kg. 
Ukratko, Sprague Dawley štakori oralno su dozirani rapamicin i derivati u dozi 2,5 ili 10 mg/kg.
represents a hydrogen atom; 
predstavlja atom vodika;
A modified soluble FGF receptor Fc fusion of claim 33 wherein said chemotherapeutic agent is selected from the group: anti-microtubule agents; platinum coordination complexes; alkylating agents; antibiotic agents; topoisomerase II Inhibitors; antimetabolites; topoisomerase I inhibitors; hormones and hormone analogues; signal transduction pathway inhibitors; non-reoeptor tyrosine kinase angiogenesis Inhibitors; immunotherapeutic agents; pro-apoptotic agents; and cell cycle signaling inhibitors. 
Modificirana fuzija između topivog FGF receptora i Fc u skladu s patentnim zahtjevom 33, naznačena time što navedeno kemoterapijsko sredstvo se bira iz skupine koju čine antimikrotubularna sredstva, platinski koordinacijski kompleksi, alkilacijska sredstva, antibiotička sredstva, inhibitori topoizomeraze Il; antimetaboliti, inhibitori topoizomeraze I, hormoni i hormonski analozi, inhibitori puteva prijenosa signala, inhibitori nereceptorske angiogene tirozin-kinaze, imunoterapijska sredstva, proapoptotska sredstva, te inhibitori signalizacije staničnog ciklusa.
The container according to any one of the previous claims, wherein the fluid guide element is arranged in the form of several parallel lines. 
Spremnik u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što je navodeći element za fluid (16, 17, 18) postavljen u obliku više paralelnih linija.
The antibody or fragment thereof according to any one of clauses 1-4, which competes with mAb 0170 for binding to SEQ ID NO: 12 or SEQ ID NO: 21 (cynomolgus monkey TREM-1). 
Antitijelo ili njegov fragment u skladu sa patentnim zahtjevom 1 ili 2, koji se natječe sa mAb 0170 za vezivanje za SEQ ID NO: 12 ili SEQ ID NO: 21 koja predstavlja aminokiselinske sekvence TREM-1 cinomolgus majmuna, gdje mAb 0170 sadrži teški lanac koji sadrži sekvencu SEQ ID NO: 4, 1 laki lanac koji sadrži sekvencu SEQ ID NO: 5.
The solid oral extended release pharmaceutical dosage form of any one of claims 53 to 56, wherein the extended release matrix formulation resists a work of at least about 0.06 J without cracking. 
Farmaceutski oblik doziranja s produljenim otpuštanjem u krutom obliku prema zahtjevu 1, 2 ili 3, naznačen time da je formulacija matrice s produljenim otpuštanjem otporna na rad od barem oko 0.06 J bez pucanja.
The method of claim 1, which does not comprise a size fractionation step after step (d). 
Postupak prema bilo kojem od zahtjeva 1 do 13, naznačen time što ne sadrži korak frakcioniranja veličine nakon koraka (d).
a valve body, said valve body defining an inlet opening, an outlet opening and a bottom; 
tijela ventila (60), pri čemu predmetno tijelo ventila (60) određuje ulazni otvor (62) i izlazni otvor (64);
The method of claim 26 wherein the ocular condition is glaucoma, and the bioactive agent comprises a prostaglandin, a carbonic anhydrase inhibitor, an a -adrenergic antagonist, or a B -adrenergic antagonist. 
Uporaba prema zahtjevu 6, gdje se bioaktivno sredstvo izabire iz skupine koja obuhvaća antivirotik, steroid za kontrolu začeća, antibiotik, analgetik, antipsihotik, prostaglandin, inhibitor karbonske anhidraze, a-adrenergički antagonist i B-adrenergički antagonist.
The titled compound is prepared analogously to 4-fluoro-3-methoxy-benzenesulfonyl chloride (Intermediate 102a) by replacing 4-fluoro-3-methoxyaniline with 5-amino-pyridine-2-carbonitrile. 
Naslovni spoj je proizveden analogno 4-fluor-3-metoksi-benzensulfonil kloridu (intermedijat 1024) zamjenom 4-fluor-3-metoksianilina s 5-amino-piridin-2-karbonitrilom.
rheumatoid arthritis, osteoporosis, cancer-associated bone disease, or Paget's disease of bone; 
reumatoidni artritis, osteoporoza, bolest kostiju povezana s rakom ili Pagetova bolest kostiju;
incubating said partly CX-REED treated liquid in said chamber, whereby the direction of electric field is reversed at intervals, 
VIII. inkubiranje navedene djelomično obrađene tekućine s CX-REED u navedenoj komori, pri čemu se smjer električnog polja preokreće u intervalima;
The integrated rotary mixer and disperser head (1) according to claim 1, wherein the leading edge (10) of each of said first plurality of impeller blades (8) is sharpened. 
Integrirana rotacijska miješalica 1 glava raspršivača (1) prema 1. tvrdnji gdje je prednji rub (10) svake od navedenog prvog mnoštva lopatica rotora (8) zaoštren.
pigments and/or fillers; 
pigmente i/ili punila naznačen time da spoj ima
A compound of formula XIII can be further transformed with base, such as K2CO3 in solvents such as DMF, THF and the like to give compounds of formula XII wherein P is defined in the discussion of scheme VI. 
Spoj formule XIII može se dalje transformirati sa bazom, kao što je K2COz u otapalima kao što su DMF, THF i slično, pri čemu se dobivaju spojevi formule XII gdje je P definiran u raspravi prikaza VI.
Controller 80, along with manual control 70 if used, can be integrated into a housing that can be positioned in the operator cab of the agricultural equipment (e.g. 
Kontrolor 80, zajedno s ručnom komandom 70, ako se koristi, može se integrirati u jedno kućište koje se može postaviti u kabinu operatera poljoprivredne opreme (npr.
HCl (2Naq., 800 mL) was added and the mixture was stirred for 15 min followed by filtration. 
Dodan je HCI (2N aq., 800 mL) te je miješanje nastavljeno tijekom 15 minuta nakon čega je slijedilo filtriranje.
This second gasket 14, second channel 12 and second aperture 13 form the outlet valve 8 . 
Ta druga brtva 14, drugi kanal 12 i druga rupica 13 tvore izlazni ventil 8.